Abstract | OBJECTIVES: DESIGN: This dose-ranging, double-masked, multicenter, phase 2 trial included subjects with CRVO for 6 months' or less duration randomly assigned (1:1:1) to receive pegaptanib sodium or sham injections every 6 weeks for 24 weeks (0.3 mg and 1 mg, n=33; sham, n=32). MAIN OUTCOME MEASURE: Visual acuity at week 30. RESULTS: In the primary analysis at week 30, 12 of 33 (36%) subjects treated with 0.3 mg of pegaptanib sodium and 13 of 33 (39%) treated with 1 mg gained 15 or more letters from baseline vs 9 of 32 (28%) sham-treated subjects (P= .48 for 0.3 mg and P= .35 for 1 mg of pegaptanib sodium vs sham). In secondary analyses, subjects treated with pegaptanib sodium were less likely to lose 15 or more letters (9% and 6%; 0.3-mg and 1-mg pegaptanib sodium groups, respectively) compared with sham-treated eyes (31%; P= .03 for 0.3 mg and P= .01 for 1 mg of pegaptanib sodium vs sham) and showed greater improvement in mean visual acuity (+7.1 and +9.9, respectively, vs -3.2 letters with sham; P= .09 for 0.3 mg and P= .02 for 1 mg of pegaptanib sodium vs sham). By week 1, the mean central retinal thickness decreased in the 0.3-mg and 1-mg pegaptanib sodium groups by 269 microm and 210 microm, respectively, vs 5 microm with sham (P< .001). CONCLUSIONS: Based on this 30-week study, intravitreous pegaptanib sodium appears to provide visual and anatomical benefits in the treatment of macular edema following CRVO. APPLICATION TO CLINICAL PRACTICE: TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00088283.
|
Authors | John J Wroblewski, John A Wells 3rd, Anthony P Adamis, Ronald R Buggage, Emmett T Cunningham Jr, Mauro Goldbaum, David R Guyer, Barrett Katz, Michael M Altaweel, Pegaptanib in Central Retinal Vein Occlusion Study Group |
Journal | Archives of ophthalmology (Chicago, Ill. : 1960)
(Arch Ophthalmol)
Vol. 127
Issue 4
Pg. 374-80
(Apr 2009)
ISSN: 1538-3601 [Electronic] United States |
PMID | 19365011
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Aptamers, Nucleotide
- Vascular Endothelial Growth Factor A
- pegaptanib
|
Topics |
- Angiogenesis Inhibitors
(administration & dosage, adverse effects)
- Aptamers, Nucleotide
(administration & dosage, adverse effects)
- Double-Blind Method
- Female
- Fluorescein Angiography
- Humans
- Injections
- Macular Edema
(drug therapy, etiology)
- Male
- Middle Aged
- Retinal Vein Occlusion
(complications, drug therapy)
- Tonometry, Ocular
- Vascular Endothelial Growth Factor A
(metabolism)
- Visual Acuity
- Vitreous Body
|